Abstract
S100 calcium-binding protein B (S100B) and glucose control are reflective of maternal-fetal risks. We investigated the value of serum S100B combined with fasting blood glucose (FBG)/hemoglobin A1c (HbA1c) in evaluating the pregnancy outcomes of patients with severe preeclampsia (SPE). The clinical characteristics of SPE patients/controls were collected. FBG/HbA1c and serum S100B levels were measured, with their correlations analyzed. SPE patients were subdivided into adverse/non-adverse outcome groups based on follow-up results. The value of different indexes in predicting pregnancy outcomes was analyzed. SPE patients showed higher systolic blood pressure, diastolic blood pressure, urine protein, and body mass index and lower platelets, gestational age at delivery, and infant birth weight than healthy controls. FBG and HbA1c were positively correlated with serum S100B. SPE patients with adverse outcomes exhibited increased serum S100B and FBG/HbA1c levels. The area under the curve of serum S100B + FBG/HbA1c in evaluating adverse pregnancy outcomes of SPE patients was 0.8412 (77.05% sensitivity/84.21% specificity), higher than either alone. Serum S100B and FBG/HbA1c were independent risk factors for adverse outcomes of SPE patients. Overall, serum S100B positively-correlates with FBG/HbA1c in SPE patients. Serum S100B and FBG/HbA1c are independent risk factors, and their combination has high value on predicting adverse pregnancy outcomes of SPE patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All the data generated or analyzed during this study are included in this published article.
References
Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61:932–42.
Nirupama R, Divyashree S, Janhavi P, Muthukumar SP, Ravindra PV. Preeclampsia: pathophysiology and management. J Gynecol Obstet Hum Reprod. 2021;50:101975.
Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:1690–702.
Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. 2021;398:341–54.
Post Uiterweer ED, Veerbeek JH, Franx A. [Pre-eclampsia]. Ned Tijdschr Tandheelkd. 2015;122:79–83.
Vaught AJ, Kovell LC, Szymanski LM, Mayer SA, Seifert SM, Vaidya D, et al. Acute cardiac effects of severe pre-eclampsia. J Am Coll Cardiol. 2018;72:1–11.
Iriyama T, Wang W, Parchim NF, Song A, Blackwell SC, Sibai BM, et al. Hypoxia-independent upregulation of placental hypoxia inducible factor-1alpha gene expression contributes to the pathogenesis of preeclampsia. Hypertension. 2015;65:1307–15.
Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma. 2006;23:1185–200.
Sun BD, Liu HM, Nie SN. S100B protein in serum is elevated after global cerebral ischemic injury. World J Emerg Med. 2013;4:165–8.
Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. 2010;75:1786–93.
Bergman L, Akhter T, Wikstrom AK, Wikstrom J, Naessen T, Akerud H. Plasma levels of S100B in preeclampsia and association with possible central nervous system effects. Am J Hypertens. 2014;27:1105–11.
Wikstrom AK, Ekegren L, Karlsson M, Wikstrom J, Bergenheim M, Akerud H. Plasma levels of S100B during pregnancy in women developing pre-eclampsia. Pregnancy Hypertens. 2012;2:398–402.
Spradley FT. Metabolic abnormalities and obesity’s impact on the risk for developing preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2017;312:R5–12.
Xu F, Yang S, Liu Y, Zheng X, Yang H, Zhang J, et al. Placental pathology and neonatal outcomes in pre-eclampsia with gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2021;34:1149–54.
Yu H, Qi X, Wang X. Application of glycated hemoglobin in the perinatal period. Int J Clin Exp Med. 2014;7:4653–9.
Cohen AL, Wenger JB, James-Todd T, Lamparello BM, Halprin E, Serdy S, et al. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy. 2014;33:81–92.
Zheng Y, Shen Y, Jiang S, Ma X, Hu J, Li C, et al. Maternal glycemic parameters and adverse pregnancy outcomes among high-risk pregnant women. BMJ Open Diabetes Res Care. 2019;7:e000774.
Kheirouri S, Ebrahimi E, Alizadeh M. Association of S100B serum levels with metabolic syndrome and its components. Acta Med Port. 2018;31:201–6.
Steiner J, Myint AM, Schiltz K, Westphal S, Bernstein HG, Walter M, et al. S100B serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance. Cardiovasc Psychiatry Neurol. 2010;2010:480707.
Steiner J, Walter M, Guest P, Myint AM, Schiltz K, Panteli B, et al. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry. 2010;15:3–4.
Wartchow KM, Tramontina AC, de Souza DF, Biasibetti R, Bobermin LD, Goncalves CA. Insulin stimulates S100B secretion and these proteins antagonistically modulate brain glucose metabolism. Neurochem Res. 2016;41:1420–9.
Gottardi E, Lecarpentier E, Villette C, Berman A, Redel D, Tsatsaris V, et al. Preeclampsia before 26 weeks of gestation: Obstetrical prognosis for the subsequent pregnancy. J Gynecol Obstet Hum Reprod. 2021;50:102000.
Takahashi N, Li F, Fushima T, Oyanagi G, Sato E, Oe Y, et al. Vitamin B(3) nicotinamide: a promising candidate for treating preeclampsia and improving fetal growth. Tohoku J Exp Med. 2018;244:243–8.
Pittara T, Vyrides A, Lamnisos D, Giannakou K. Pre-eclampsia and long-term health outcomes for mother and infant: an umbrella review. BJOG. 2021;128:1421–30.
Michetti F, Gazzolo D. S100B protein in biological fluids: a tool for perinatal medicine. Clin Chem. 2002;48:2097–104.
Nagdyman N, Komen W, Ko HK, Muller C, Obladen M. Early biochemical indicators of hypoxic-ischemic encephalopathy after birth asphyxia. Pediatr Res. 2001;49:502–6.
Farrar D, Simmonds M, Bryant M, Sheldon TA, Tuffnell D, Golder S, et al. Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and meta-analysis. BMJ. 2016;354:i4694.
Ukah UV, De Silva DA, Payne B, Magee LA, Hutcheon JA, Brown H, et al. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: a systematic review. Pregnancy Hypertens. 2018;11:115–23.
Wu J, Sheng X, Zhou S, Fang C, Song Y, Wang H, et al. Clinical significance of S100B protein in pregnant woman with early- onset severe preeclampsia. Ginekol Pol. 2021. https://doi.org/10.5603/GP.a2021.0126.
Vettorazzi J, Torres FV, de Avila TT, Martins-Costa SH, Souza DO, Portela LV, et al. Serum S100B in pregnancy complicated by preeclampsia: a case-control study. Pregnancy Hypertens. 2012;2:101–5.
Johns EC, Denison FC, Norman JE, Reynolds RM. Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab. 2018;29:743–54.
Cao W, Wang X, Chen T, Xu W, Feng F, Zhao S, et al. Maternal lipids, BMI and IL-17/IL-35 imbalance in concurrent gestational diabetes mellitus and preeclampsia. Exp Ther Med. 2018;16:427–35.
Vestgaard M, Sommer MC, Ringholm L, Damm P, Mathiesen ER. Prediction of preeclampsia in type 1 diabetes in early pregnancy by clinical predictors: a systematic review. J Matern Fetal Neonatal Med. 2018;31:1933–9.
Busse M, Scharm M, Oettel A, Redlich A, Costa SD, Zenclussen AC. Enhanced S100B expression in T and B lymphocytes in spontaneous preterm birth and preeclampsia. J Perinat Med. 2022;50:157–66.
Misan N, Michalak S, Kapska K, Osztynowicz K, Ropacka-Lesiak M, Kawka-Paciorkowska K. Does the blood-brain barrier integrity change in regard to the onset of fetal growth restriction? Int J Mol Sci. 2023;24:1965.
Roka A, Kelen D, Halasz J, Beko G, Azzopardi D, Szabo M. Serum S100B and neuron-specific enolase levels in normothermic and hypothermic infants after perinatal asphyxia. Acta Paediatr. 2012;101:319–23.
Park JS, Kim DW, Kwon JY, Park YW, Kim YH, Cho HY. Development of a screening tool for predicting adverse outcomes of gestational diabetes mellitus: a retrospective cohort study. Medicine. 2016;95:e2204.
Gou BH, Guan HM, Bi YX, Ding BJ. Gestational diabetes: weight gain during pregnancy and its relationship to pregnancy outcomes. Chin Med J. 2019;132:154–60.
Florio P, Marinoni E, Di Iorio R, Bashir M, Ciotti S, Sacchi R, et al. Urinary S100B protein concentrations are increased in intrauterine growth-retarded newborns. Pediatrics. 2006;118:e747–54.
Hong JGS, Fadzleeyanna MYN, Omar SZ, Tan PC. HbA1c at term delivery and adverse pregnancy outcome. BMC Pregnancy Childbirth. 2022;22:679.
Zawiejska A, Wroblewska-Seniuk K, Gutaj P, Mantaj U, Gomulska A, Kippen J, et al. Early screening for gestational diabetes using IADPSG criteria may be a useful predictor for congenital anomalies: preliminary data from a high-risk population. J Clin Med. 2020;9:3553.
Xiao J, Fan W, Zhu Q, Shi Z. Diagnosis of proteinuria using a random urine protein-creatinine ratio and its correlation with adverse outcomes in pregnancy with preeclampsia characterized by renal damage. J Clin Hypertens. 2022;24:652–9.
Strzalko B, Karowicz-Bilinska A, Wyka K, Krajewski P, Kesiak M, Kociszewska-Najman B. Serum S100B Protein Concentrations in SGA/FGR newborns. Ginekol Pol. 2021.
Xiao Y, Zhang X. Association between maternal glucose/lipid metabolism parameters and abnormal newborn birth weight in gestational diabetes complicated by preeclampsia: a retrospective analysis of 248 cases. Diabetes Ther. 2020;11:905–14.
Sekitoleko I, Tino S, Mubiru M, Nansubuga F, Zaake D, Nakabuye B, et al. The influence of fasting and post-load glucose levels on maternal and neonatal outcomes in women with hyperglycaemia in pregnancy in Uganda: a prospective observational cohort study. Diabetes Res Clin Pract. 2022;191:110049.
Author information
Authors and Affiliations
Contributions
All contributions were from AY.
Corresponding author
Ethics declarations
Competing interests
All author declares no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yan, A. Application value of serum S100B combined with glucose metabolism indexes in predicting adverse pregnancy outcomes of patients with severe preeclampsia. J Hum Hypertens 38, 232–237 (2024). https://doi.org/10.1038/s41371-023-00887-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41371-023-00887-x